These results indicated p-ERK1/2 inhibition partially prevented the deterioration of CRC induced by insulin and OA and promoted cell apoptosis, indicating that p-ERK1/2 might be a potential target for T2D-associated CRC treatment. This evidence concerns the gene MAPK3 and colorectal carcinoma.